Publications by authors named "B Gastman"
Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.
J Immunother Cancer
January 2025
In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved for patients with disease refractory to immune checkpoint inhibitors. Since the advent of chimeric antigen receptor (CAR) T cells for patients with hematological malignancies, a growing network of centers capable of delivering effector T cell products to patients has developed.
View Article and Find Full Text PDFArticle Synopsis
- * Results showed that the median relapse-free survival (RFS) was longer for the IO group compared to the TT group, but most patients were alive at the end of the study; however, more patients in the IO group faced severe treatment-related side effects.
- * The findings suggest that while both therapies can lead to prolonged RFS, TT might have lower tolerance in practice, and there’s a need for further analysis to assess the overall survival benefits over a longer period.
Background: Treatment options for immunotherapy-refractory melanoma are an unmet need. The MASTERKEY-115 phase II, open-label, multicenter trial evaluated talimogene laherparepvec (T-VEC) plus pembrolizumab in advanced melanoma that progressed on prior programmed cell death protein-1 (PD-1) inhibitors.
Methods: Cohorts 1 and 2 comprised patients (unresectable/metastatic melanoma) who had primary or acquired resistance, respectively, and disease progression within 12 weeks of their last anti-PD-1 dose.